News

Thursday July 6, 2023

Positive findings from recent SAB meeting

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Positive findings from recent Scientific Advisory Board meeting Confirms proposed Phase 3 development pathway and identifies new life cycle management targets for […]

Thursday June 29, 2023

Business Update

Business Update Continued progress on XF-73 partnering discussions Susan Koppy appointed to drive business development activities $2bn XF-73 Nasal market opportunity Brighton, United Kingdom – 29th June 2023: Destiny Pharma plc (AIM: […]

Thursday May 25, 2023

Result of 2023 Annual General Meeting

Destiny Pharma plc (“Destiny Pharma” or “the Company”)  Result of Annual General Meeting Brighton, United Kingdom – 25 May 2023 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company […]

Thursday May 25, 2023

Dr Debra Barker Appointed Interim CEO

Board Changes Dr Debra Barker Appointed Interim CEO Brighton, United Kingdom – 25th May 2023: Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development […]

Friday May 19, 2023

New Destiny Pharma animations for NTCD-M3 and XF-73 uploaded to website

Check out our new animations explaining how NTCD-M3 and XF-73 work to prevent infections.  Find them via the links below:- NTCD-M3   https://destinypharma.com/pipeline/ntcd-m3/ XF-73   https://destinypharma.com/pipeline/xf-73-nasal/

Tuesday May 2, 2023

Positive results from SPOR-COV® research

Destiny Pharma and SporeGen® announce update from research collaboration under Innovate UK grant award to develop a biotherapeutic treatment (SPOR-COV®) for COVID-19 and Influenza Positive results from testing SPOR-COV in […]

Wednesday April 26, 2023

Posting of Annual Report and Accounts, and Notice of AGM

Destiny Pharma plc (“Destiny Pharma” or “the Company”)  Posting of Annual Report and Accounts, and Notice of AGM   Brighton, United Kingdom – 26 April 2023 – Destiny Pharma plc (AIM: DEST) […]

Thursday April 13, 2023

Audited results for year ended 31 December 2022

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Audited results for the year ended 31 December 2022 Exclusive North American partnering deal worth up to $570m plus royalties secured for […]

Tuesday April 4, 2023

Landmark data published on NTCD-M3

Destiny Pharma plc(“Destiny Pharma” or “the Company”) Landmark data published on successful NTCD‐M3gut colonisation after fidaxomicin administration Brighton, United Kingdom ‐ 4 April 2023 ‐ Destiny Pharma (AIM: DEST), a clinical stage innovative […]

Monday April 3, 2023

Notice of Results and Investor Presentation

Destiny Pharma plc (“Destiny Pharma” or “the Company”)  Notice of Full Year Results and Investor Presentation Brighton, United Kingdom – 3 April 2023 – Destiny Pharma plc (AIM: DEST), a clinical stage […]